©2022 Stanford Medicine
Estrogen Use in Protection From Cognitive Decline
Not Recruiting
Trial ID: NCT00097058
Purpose
This study is designed to assess the effects of estrogen therapy among postmenopausal women
at risk for cognitive decline.
Official Title
Estrogen Use in Protection From Cognitive Decline
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Women between the ages of 45 and 65
- Currently on hormone replacement
- One year or more post complete cessation of menses
- Willing to sign the Human Subject Protection Consent form prior to enrollment in the
study
- Willing to be randomized to continue or discontinue estrogen therapy
- Adequately visually and auditorially acute to allow neuropsychological testing
- Beyond 8 years of educational achievement to allow adequate neuropsychological testing
- Willing to undergo brain imaging
- At risk for cognitive decline, as defined by one or more of the following: Personal or
family history of mood disorder, Hypothyroidism, Diabetes, Family history of
Alzheimer's, APOE-4 allele
Exclusion Criteria:
- Diagnosis of possible or probable Alzheimer's disease or dementia
- Cerebrovascular disease or uncontrolled hypertension (systolic BP >170 or diastolic BP
>100)
- History of myocardial infarction within previous year or unstable heart disease
- History of significant liver disease, pulmonary disease, or current cancer
- Contraindication for MRI (metal in body, claustrophobia, etc.)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305